Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.58% | 9.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.22% | -5.54% | |||
| Operating Income | -33.22% | 5.54% | |||
| Income Before Tax | -19.81% | -4.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.81% | -4.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.81% | -4.56% | |||
| EBIT | -33.22% | 5.54% | |||
| EBITDA | -33.26% | 5.55% | |||
| EPS Basic | -16.83% | -4.58% | |||
| Normalized Basic EPS | -16.85% | -4.58% | |||
| EPS Diluted | -16.83% | -4.58% | |||
| Normalized Diluted EPS | -16.85% | -4.58% | |||
| Average Basic Shares Outstanding | 2.51% | 0.05% | |||
| Average Diluted Shares Outstanding | 2.51% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||